Peter Rosenorn
Latest From Peter Rosenorn
Scaling Up For First Product Launch: Seven Hazards To Avoid
As the margin for error in the drug launch cycle continues to erode, emerging biopharma companies face a growing urgency to double down on scaling up for their first launch.